A population pharmacokinetic model of remdesivir and its major metabolites based on published mean values from healthy subjects.

Abouellil, Ahmed; Bilal, Muhammad; Taubert, Max; Fuhr, Uwe

Abouellil, Ahmed; Bilal, Muhammad; Taubert, Max; Fuhr, Uwe.

Afiliação

Abouellil A; Faculty of Medicine, Center for Pharmacology, Department I of Pharmacology, University Hospital Cologne, University of Cologne, Gleueler Straße 24, 50931, Cologne, Germany. s4ahabou@uni-bonn.de.
Bilal M; Immunosensation Cluster of Excellence, University Hospital Bonn, Bonn, Germany. s4ahabou@uni-bonn.de.
Taubert M; Faculty of Medicine, Center for Pharmacology, Department I of Pharmacology, University Hospital Cologne, University of Cologne, Gleueler Straße 24, 50931, Cologne, Germany.
Fuhr U; Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, Bonn, Germany.

Naunyn Schmiedebergs Arch Pharmacol ; 396(1): 73-82, 2023 01.

Article em En | MEDLINE | ID: mdl-36123499

Assuntos

COVID-19; Humanos; SARS-CoV-2; Voluntários Saudáveis; Pandemias; Tratamento Farmacológico da COVID-19

Palavras-chave

Anti-virals; COVID-19; GS-441524; GS-704277; Pharmacometrics; Population pharmacokinetics; Remdesivir

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Revista: Naunyn Schmiedebergs Arch Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google